DEVELOPMENT OF A NEW DETECTION DEVICE
Axion Biosystems specializes in neural interfacing technologies with wide applicability to the research, clinical, and drug discovery markets. Their proprietary technology allows simultaneous stimulation and recording of neural tissue, “an industry first”, and includes low-power chips that service thousands of channels. While current development is focused on pharmaceutical drug screening, ongoing development will result in devices in the medical arena. I led design efforts for the development of their newest portable MEA device.
Axion Biosystems has developed the next generation multi-electrode array (MEA) technology to provide unprecedented access to cellular information at a reasonable cost. This proprietary technology addresses two challenges that have existed in the cellular analysis field. First, they have eliminated the long-lasting stimulation artifacts from the electrophysiological tissue response, enabling simultaneous stimulation and recording. Second, they have created fabrication methods for low-cost microelectrode arrays. The combination of these developments allows for high throughput cell-based